title: Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine.
abstract: The anti-metabolite chemotherapeutic, gemcitabine is relatively effective for a spectrum of neoplastic conditions that include various forms of leukemia and adenocarcinoma/carcinoma. Rapid systemic deamination of gemcitabine accounts for a brief plasma half-life but its sustained administration is often curtailed by sequelae and chemotherapeutic-resistance. A molecular strategy that diminishes these limitations is the molecular design and synthetic production of covalent gemcitabine immunochemotherapeutics that possess properties of selective "targeted" delivery. The simultaneous dual selective "targeted" delivery of gemcitabine at two separate sites on the external surface membrane of a single cancer cell types represents a therapeutic approach that can increase cytosol chemotherapeutic deposition; prolong chemotherapeutic plasma half-life (reduces administration frequency); minimize innocent exposure of normal tissues and healthy organ systems; and ultimately enhance more rapid and thorough resolution of neoplastic cell populations.
  
  
  METHODS
  A light-reactive gemcitabine intermediate synthesized utilizing succinimidyl 4,4-azipentanoate was covalently bound to anti-EGFR or anti-HER2/neuIgG by exposure to UV light (354-nm) resulting in the synthesis of covalent immunochemotherapeutics, gemcitabine-(C4-amide)-[anti-EGFR] and gemcitabine-(C4-amide)-[anti-HER2/neu]. Cytotoxic anti-neoplastic potency of gemcitabine-(C4-amide)-[anti-EGFR] and gemcitabine-(C4-amide)-[anti-HER2/neu] between gemcitabine-equivalent concentrations of 10-12M and 10-6M was determined utilizing chemotherapeutic-resistant mammary adenocarcinoma (SKRr-3). The organoselenium compound, [Se]-methylselenocysteine was evaluated to determine if it complemented the anti-neoplastic potency of the covalent gemcitabine immunochemotherapeutics.
  
  
  RESULTS
  Gemcitabine-(C4-amide)-[anti-EGFR], gemcitabine-(C4-amide)-[anti-HER2/neu] and the dual simultaneous combination of gemcitabine-(C4-amide)-[anti-EGFR] with gemcitabine-(C4-amide)-[anti-HER2/neu] all had anti-neoplastic cytotoxic potency against mammary adenocarcinoma. Gemcitabine-(C4-amide)-[anti-EGFR] and gemcitabine-(C4-amide)-[anti-HER2/neu] produced progressive increases in anti-neoplastic cytotoxicity that were greatest between gemcitabine-equivalent concentrations of 10-9M and 10-6M. Dual simultaneous combinations of gemcitabine-(C4-amide)-[anti-EGFR] with gemcitabine-(C4-amide)-[anti-HER2/neu] produced levels of anti-neoplastic cytotoxicity intermediate between each of the individual covalent gemcitabine immunochemotherapeutics. Total anti-neoplastic cytotoxicity of the dual simultaneous combination of gemcitabine-(C4-amide)-[anti-EGFR] and gemcitabine-(C4-amide)-[anti-HER2/neu] against chemotherapeutic-resistant mammary adenocarcinoma (SKBr-3) was substantially higher when formulated with [Se]-methylsele-nocysteine.
authors.affiliation: Department of Basic Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, USA.
authors.forename: C P
authors.initials: CP
authors.lastname: Coyne
authors.affiliation: Department of Basic Sciences, College of Veterinary Medicine, Mississippi State University, Mississippi State, USA.
authors.forename: Toni
authors.initials: T
authors.lastname: Jones
authors.affiliation: Wise Center, Mississippi State University, Mississippi State, USA.
authors.forename: Ryan
authors.initials: R
authors.lastname: Bear
keywords: Anti-EGFR; Anti-HER2/neu; Covalent Immunochemotherapeutic; Gemcitabine; Gemcitabine-(C4-amide)-[Anti-EGFR]; Gemcitabine-(C4-amide)-[Anti-HER2/neu]; Mammary Adenocarcinoma (SKBr-3); [Se]-Methylselenocysteine
references.citation: Biochem Pharmacol. 2007 May 1;73(9):1280-7
references.pmid: 17239826
references.citation: Pharmacol Res. 2004 Nov;50(5):487-98
references.pmid: 15458769
references.citation: Anticancer Agents Med Chem. 2008 Jun;8(5):488-96
references.pmid: 18537532
references.citation: J Control Release. 1998 Jul 31;54(2):223-33
references.pmid: 9724909
references.citation: Rev Recent Clin Trials. 2007 May;2(2):111-6
references.pmid: 18473995
references.citation: Biosens Bioelectron. 2009 Mar 15;24(7):2268-72
references.pmid: 19101136
references.citation: Biotechnol Appl Biochem. 2005 Apr;41(Pt 2):137-43
references.pmid: 15202936
references.citation: Anticancer Drugs. 2001 Feb;12(2):107-16
references.pmid: 11261883
references.citation: Br J Cancer. 2008 Sep 2;99(5):760-7
references.pmid: 18728667
references.citation: Bioorg Med Chem. 1995 Oct;3(10 ):1305-12
references.pmid: 8564396
references.citation: Clin Cancer Res. 2007 May 1;13(9):2795-803
references.pmid: 17473213
references.citation: Eur J Drug Metab Pharmacokinet. 2007 Apr-Jun;32(2):101-8
references.pmid: 17702197
references.citation: Anticancer Res. 2010 Feb;30(2):473-80
references.pmid: 20332457
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2006 May 1;835(1-2):136-42
references.pmid: 16584929
references.citation: Mol Biother. 1989;1(5):250-5
references.pmid: 2515870
references.citation: Clin Cancer Res. 2004 Apr 1;10 (7):2561-9
references.pmid: 15073137
references.citation: Breast Cancer Res. 2011 Apr 21;13(2):R46
references.pmid: 21510863
references.citation: J Org Chem. 1999 Oct 29;64(22):8319-8322
references.pmid: 11674754
references.citation: Br J Pharmacol. 2008 Sep;155(2):185-97
references.pmid: 18574456
references.citation: J Biomed Mater Res B Appl Biomater. 2010 Jul;94(1):187-95
references.pmid: 20524194
references.citation: J Clin Oncol. 2002 Feb 1;20(3):719-26
references.pmid: 11821453
references.citation: Adv Exp Med Biol. 2007;608:1-22
references.pmid: 17993229
references.citation: Eur J Pharm Sci. 2004 Dec;23(4-5):393-7
references.pmid: 15567293
references.citation: Clin Cancer Res. 2006 Jan 15;12 (2):600-7
references.pmid: 16428506
references.citation: Blood. 2012 Apr 19;119(16):3767-78
references.pmid: 22271448
references.citation: Mol Cancer Ther. 2006 Oct;5(10):2540-8
references.pmid: 17041098
references.citation: Int J Cancer. 2004 Nov 10;112(3):492-501
references.pmid: 15382077
references.citation: Anticancer Res. 2000 May-Jun;20(3A):1391-414
references.pmid: 10928049
references.citation: Oncol Rep. 2007 Oct;18(4):893-9
references.pmid: 17786352
references.citation: J Drug Target. 2002 Nov;10(7):567-71
references.pmid: 12683724
references.citation: Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70
references.pmid: 10482195
references.citation: Biochem Biophys Res Commun. 2011 Apr 8;407(2):412-9
references.pmid: 21402055
references.citation: Oncogene. 2006 Apr 20;25(17 ):2509-19
references.pmid: 16518418
references.citation: Cancer Chemother Pharmacol. 2010 Oct;66(5):899-911
references.pmid: 20066420
references.citation: Science. 1987 Jan 9;235(4785):177-82
references.pmid: 3798106
references.citation: Cell Oncol (Dordr). 2014 Dec;37(6):421-8
references.pmid: 25410120
references.citation: J Med Chem. 2003 Sep 11;46(19):4205-8
references.pmid: 12954073
references.citation: Anticancer Drugs. 1997 Feb;8(2):199-203
references.pmid: 9073316
references.citation: Curr Pharm Des. 2005;11(9):1079-89
references.pmid: 15853657
references.citation: Breast Cancer Res Treat. 2009 Nov;118(1):33-43
references.pmid: 18855134
references.citation: Cancer Immunol Immunother. 1994 Feb;38(2):92-8
references.pmid: 8306371
references.citation: J Clin Oncol. 2008 Apr 20;26(12):1993-9
references.pmid: 18421051
references.citation: Nat Clin Pract Oncol. 2008 Sep;5(9):512-20
references.pmid: 18594499
references.citation: J Chemother. 2008 Oct;20(5):632-9
references.pmid: 19028628
references.citation: J Biomol Screen. 2004 Sep;9(6):506-15
references.pmid: 15452337
references.citation: Anticancer Drugs. 2009 Nov;20(10):851-5
references.pmid: 19826350
references.citation: Drug Metab Dispos. 2001 Mar;29(3):313-8
references.pmid: 11181501
references.citation: Bioorg Med Chem Lett. 2005 May 16;15(10):2571-4
references.pmid: 15863318
references.citation: J Natl Cancer Inst. 1988 Sep 21;80(14):1154-9
references.pmid: 3261803
references.citation: Cancer Res. 2009 Mar 15;69(6):2191-4
references.pmid: 19276389
references.citation: Biochem Pharmacol. 2010 Jul 1;80(1):72-9
references.pmid: 20298675
references.citation: Biochem Pharmacol. 2004 Feb 1;67(3):513-22
references.pmid: 15037203
references.citation: Yao Xue Xue Bao. 1992;27(5):325-30
references.pmid: 1442051
references.citation: Oncol Rep. 2010 May;23 (5):1469-75
references.pmid: 20372866
references.citation: Anticancer Res. 2000 Mar-Apr;20(2A):799-808
references.pmid: 10810357
references.citation: Cancer Res. 2008 Nov 15;68(22):9280-90
references.pmid: 19010901
references.citation: Oncogene. 2004 Apr 29;23(20):3613-21
references.pmid: 15034547
references.citation: Tumour Biol. 1991;12(4):198-206
references.pmid: 1651554
references.citation: J Leukoc Biol. 1998 Jan;63(1):131-7
references.pmid: 9469483
references.citation: Anticancer Drugs. 2000 Jun;11(5):377-84
references.pmid: 10912954
references.citation: Mol Cancer Ther. 2009 Aug;8(8):2152-62
references.pmid: 19671734
references.citation: Bioorg Med Chem. 2011 Jan 1;19(1):67-76
references.pmid: 21169024
references.citation: Ann Oncol. 2011 Jun;22(6):1308-17
references.pmid: 21119031
references.citation: BMC Cancer. 2010 Jul 30;10:397
references.pmid: 20673348
references.citation: Bioconjug Chem. 2008 Jul;19(7):1414-22
references.pmid: 18578486
references.citation: Anticancer Res. 1995 Jul-Aug;15(4):1387-93
references.pmid: 7654026
references.citation: Cancer Chemother Pharmacol. 2005 Jul;56(1):15-21
references.pmid: 15789226
references.citation: Biotherapy. 1997;10(2):145-59
references.pmid: 9373737
references.citation: Oncogene. 1998 Oct 29;17(17):2235-49
references.pmid: 9811454
references.citation: J Drug Target. 2009 Jul;17(6):474-89
references.pmid: 19480561
references.citation: Nano Lett. 2007 Nov;7(11):3305-14
references.pmid: 17918903
references.citation: Pharm Res. 2001 Jan;18(1):29-38
references.pmid: 11336350
references.citation: Anticancer Res. 2010 Nov;30(11):4673-7
references.pmid: 21115922
references.citation: Mol Pharm. 2006 Nov-Dec;3(6):737-44
references.pmid: 17140261
references.citation: Curr Cancer Drug Targets. 2010 Dec;10(8):824-33
references.pmid: 20718704
references.citation: Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12128-33
references.pmid: 18713866
references.citation: Int J Oncol. 2010 Sep;37(3):669-78
references.pmid: 20664936
references.citation: Eur J Cancer. 2007 Jan;43(2):433-42
references.pmid: 17097285
references.citation: Anticancer Drugs. 2006 Jan;17(1):53-61
references.pmid: 16317290
references.citation: Cancer Chemother Pharmacol. 2001 Aug;48(2):169-76
references.pmid: 11561783
references.citation: Bioconjug Chem. 1999 Jan-Feb;10(1):9-17
references.pmid: 9893958
references.citation: Clin Cancer Res. 2007 Aug 15;13(16):4909-19
references.pmid: 17699871
references.citation: J Drug Target. 2003 Feb;11(2):101-7
references.pmid: 12881196
references.citation: Leuk Res. 1996 Jan;20(1):37-45
references.pmid: 8632676
references.citation: Anticancer Agents Med Chem. 2009 Jul;9(6):703-15
references.pmid: 19601750
references.citation: Chemotherapy. 2008;54(3):194-200
references.pmid: 18560226
references.citation: Cancer Res. 2006 Oct 15;66(20):10100-11
references.pmid: 17047074
references.citation: J Cancer Ther. 2012 Oct;3(5A):689-711
references.pmid: 26225216
references.citation: Acta Biomater. 2010 Jun;6(6):1968-77
references.pmid: 20025999
references.citation: Cancer Immunol Immunother. 2009 Nov;58(11):1887-96
references.pmid: 19340424
references.citation: Biomaterials. 2008 Oct;29(28):3856-65
references.pmid: 18606445
references.citation: Biol Direct. 2011 Jan 26;6:5
references.pmid: 21269489
references.citation: Cancer Chemother Pharmacol. 2006 Jan;57(1):105-13
references.pmid: 16133534
references.citation: Proc Natl Acad Sci U S A. 1989 May;86(10):3778-81
references.pmid: 2786202
references.citation: ACS Appl Mater Interfaces. 2010 May;2(5):1384-9
references.pmid: 20420365
references.citation: Biomed Pharmacother. 2004 Nov;58(9):520-6
references.pmid: 15511610
references.citation: Cancer Chemother Pharmacol. 2010 Apr;65(5):903-11
references.pmid: 19685055
references.citation: Int J Oncol. 2003 Sep;23(3):665-72
references.pmid: 12888902
references.citation: Biochem Biophys Res Commun. 1981 Oct 15;102(3):1048-54
references.pmid: 7306187
references.citation: Blood. 2011 Apr 28;117(17):4530-41
references.pmid: 21228331
references.citation: Cancer Chemother Pharmacol. 2009 Jul;64(2):413-8
references.pmid: 19229536
references.citation: Clin Ther. 2008 Aug;30(8):1426-47
references.pmid: 18803986
references.citation: N Engl J Med. 2001 Mar 15;344(11):783-92
references.pmid: 11248153
references.citation: Cancer Immunol Immunother. 2007 Jan;56(1):35-47
references.pmid: 16636810
references.citation: J Clin Oncol. 1999 Sep;17(9):2639-48
references.pmid: 10561337
references.citation: Cancer Res. 2007 Nov 15;67(22):10984-92
references.pmid: 18006844
references.citation: Clin Cancer Res. 2008 Nov 1;14(21):6730-4
references.pmid: 18980964
references.citation: J Med Chem. 1996 Aug 30;39(18):3451-60
references.pmid: 8784442
references.citation: Biochem J. 1996 Nov 15;320 ( Pt 1):293-300
references.pmid: 8947500
references.citation: Cancer Res. 2002 Apr 1;62(7):2034-42
references.pmid: 11929822
references.citation: Cancer Lett. 2009 Sep 8;282(1):87-97
references.pmid: 19345476
references.citation: Reprod Biol Endocrinol. 2007 Sep 25;5:38
references.pmid: 17894888
references.citation: Ann Hematol. 2009 Aug;88(8):733-42
references.pmid: 19153735
references.citation: Oncology. 2001;61 Suppl 2:50-7
references.pmid: 11694788
references.citation: Lung Cancer. 2003 Oct;42(1):97-102
references.pmid: 14512193
references.citation: Biomaterials. 2009 Jul;30(20):3466-75
references.pmid: 19304320
references.citation: Semin Oncol. 2000 Dec;27(6 Suppl 11):21-5; discussion 92-100
references.pmid: 11236023
references.citation: Bioorg Med Chem Lett. 2009 Aug 15;19(16):4764-7
references.pmid: 19574048
references.citation: Cancer Res. 1999 Jan 1;59(1):115-21
references.pmid: 9892195
references.citation: Semin Oncol. 2001 Feb;28(1 Suppl 3):13-9
references.pmid: 11301370
references.citation: Bioorg Med Chem Lett. 2005 Nov 15;15(22):5071-5
references.pmid: 16168650
references.citation: Clin Cancer Res. 1999 Apr;5(4):909-16
references.pmid: 10213228
references.citation: Int J Pharm. 2010 May 31;391(1-2):212-20
references.pmid: 20214970
references.citation: Anticancer Res. 2007 Sep-Oct;27(5A):3075-82
references.pmid: 17970047
references.citation: Cancer Biother Radiopharm. 2012 Feb;27(1):41-55
references.pmid: 22191802
references.citation: Mol Pharm. 2010 Dec 6;7(6):2255-69
references.pmid: 20958082
references.citation: Eur J Med Chem. 2008 Jun;43(6):1336-43
references.pmid: 17949859
references.citation: Toxicol In Vitro. 2008 Feb;22(1):232-9
references.pmid: 17904330
references.citation: Cancer Immunol Immunother. 1988;27(3):267-71
references.pmid: 3180150
references.citation: Cancer Lett. 2010 Aug 28;294(2):211-9
references.pmid: 20193978
references.citation: J Chromatogr B Biomed Appl. 1996 Jun 28;682(1):115-23
references.pmid: 8832432
references.citation: Proc Natl Acad Sci U S A. 1988 Feb;85(4):1189-93
references.pmid: 3422487
references.citation: Breast Cancer. 2011 Jul;18(3):203-12
references.pmid: 21465229
references.citation: J Cancer Ther. 2011 Mar;2(1):22-39
references.pmid: 26229727
references.citation: Exp Oncol. 2009 Jun;31(2):123-4
references.pmid: 19550405
references.citation: Mol Cancer. 2006 Sep 05;5:34
references.pmid: 16953886
references.citation: J Pharmacol Exp Ther. 2011 May;337(2):423-32
references.pmid: 21262849
references.citation: Invest New Drugs. 2007 Aug;25(4):313-26
references.pmid: 17483874
references.citation: Mol Cancer Ther. 2007 Mar;6(3):1031-8
references.pmid: 17339365
references.citation: PLoS One. 2009 Oct 02;4(10 ):e7287
references.pmid: 19806185
references.citation: J Pharm Biomed Anal. 2003 Dec 4;33(5):1093-102
references.pmid: 14656600
references.citation: Cancer Res. 1995 Jun 1;55(11):2352-6
references.pmid: 7757986